This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)
This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT) between 2011 and 2016. The primary end points are overall survival (OS) and progression free survival (PFS) with Kaplan Meier. This study was approved by Ethical Committee in Dharmais National Cancer Hospital.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
122
Dharmais National Cancer Center Hospital
Jakarta, Indonesia
Overall survival
length of time from the date of pathological diagnosis until death from any cause
Time frame: time from the date of pathological diagnosis until death from any cause and until minimum sample sizes are met and an average 3 years
Progressive free survival
length of time from after treatment until tumor progression or death from any cause
Time frame: time from after treatment until tumor progression or death from any cause and until minimum sample sizes are met and an average 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Comparison of efficacy with hormonal therapy
Comparison of efficacy with chemotherapy
Comparison of efficacy with chemotherapy